Diabetes Mellitus, Type 2
Conditions
Keywords
Diabetes Mellitus, Type 2, Canagliflozin, JNJ-28431754, Pharmacokinetics, Pharmacodynamics, Children, Adolescents
Brief summary
The purpose of this study is to evaluate the pharmacokinetics (blood levels) and pharmacodynamics (the action or effects a drug has on the body) of canagliflozin in children and adolescents with type 2 diabetes mellitus aged 10 to 17 years (inclusive). Other purposes are to investigate safety and assess the ease of swallowing the tablets.
Detailed description
The participants who meet the eligibility criteria, will receive a single dose of placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) and this will be followed by baseline 24 hour pharmacodynamic assessments. On the next morning participants will receive the first canagliflozin dose and will be discharged home to continue canagliflozin treatment for 13 additional days. There will be 2 treatment groups (8 participants in each): the first group will receive canagliflozin 100 mg daily, the second group will receive either canagliflozin 300 mg or canagliflozin 50 mg daily. The canagliflozin dose for the second treatment group will be determined after the sponsor has evaluated the results from the first 5 participants. On day 14 of treatment the participants will be admitted again for 24 hour pharmacokinetic and pharmacodynamics assessments. The participants will continue to take their normal dose and schedule of metformin during the entire study. The total duration of the study is approximately 50 days.
Interventions
One 100-mg tablet of canagliflozin orally administered daily for 14 days.
One 50-mg tablet of canagliflozin orally administered daily for 14 days.
One 300-mg tablet of canagliflozin orally administered daily for 14 days.
DRUGPlacebo
One matching placebo tablet orally administered at baseline phase.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosed with Type 2 Diabetes Mellitus * Be on a stable regimen of metformin immediate release (IR) monotherapy of at least 1,000 mg/day for at least 8 weeks before screening * Able to swallow whole tablets * Absence of pancreatic autoimmunity * Participants and their caregivers must agree to perform the fasting fingerstick glucose self-monitoring during the study
Exclusion criteria
* History of Type 1 diabetes mellitus * History of maturity onset diabetes of the young (MODY) and any secondary form of diabetes * Current clinically significant medical illness e.g., significant pulmonary disease, renal or hepatic insufficiency, uncontrolled thyroid disease * Systolic or diastolic blood pressure outside the range considered normal for the participant sex, age and height * For females, participants will be excluded if pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentrations of canagliflozin following multiple oral doses of canagliflozin | From Days 14 to 17 | Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma glucose concentration following multiple oral doses of canagliflozin | From Days -1 to 1, and from Days 14 to 15 | Plasma glucose is equal to the amount of glucose in the plasma at the defined time points. |
| Urine glucose excretion following multiple oral doses of canagliflozin | From Days -1 to 1, and from Days 14 to 15 | Urine glucose excretion is equal to the amount of glucose excreted into the urine over defined time intervals. |
| Renal threshold for glucose excretion following multiple oral doses of canagliflozin | From Days -1 to 1, and from Days 14 to 15 | Renal threshold is defined as the plasma glucose concentration above which glucose is excreted in the urine. |
| Acceptability of the canagliflozin tablet | Day 14 | A questionnaire containing 5 questions about the acceptability of the tablet (taste, smell, swallowability, residual mouth taste, and overall feeling) will be administered to the participants at the end of the treatment phase. Each question is rated using a 5 or 6-point scale. The scales comprise the following outcomes: very negative, negative, neutral, positive, and very positive. Results will be summarized descriptively. |
| Number of participants with adverse events as a measure of safety and tolerability | Approximately 50 days | — |
Countries
Brazil, United States
Outcome results
None listed